Pfizer Inc. (PFE)
NYSE: PFE · IEX Real-Time Price · USD
25.67
+0.03 (0.12%)
Apr 30, 2024, 12:20 PM EDT - Market open
Pfizer Employees
Pfizer had 88,000 employees on December 31, 2023. The number of employees increased by 5,000 or 6.02% compared to the previous year.
Employees
88,000
Change (1Y)
5,000
Growth (1Y)
6.02%
Revenue / Employee
$664,727
Profits / Employee
$24,080
Market Cap
145.07B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 88,000 | 5,000 | 6.02% |
Dec 31, 2022 | 83,000 | 4,000 | 5.06% |
Dec 31, 2021 | 79,000 | 500 | 0.64% |
Dec 31, 2020 | 78,500 | -9,800 | -11.10% |
Dec 31, 2019 | 88,300 | -4,100 | -4.44% |
Dec 31, 2018 | 92,400 | 2,200 | 2.44% |
Dec 31, 2017 | 90,200 | -6,300 | -6.53% |
Dec 31, 2016 | 96,500 | -1,400 | -1.43% |
Dec 31, 2015 | 97,900 | 19,600 | 25.03% |
Dec 31, 2014 | 78,300 | 600 | 0.77% |
Dec 31, 2013 | 77,700 | -13,800 | -15.08% |
Dec 31, 2012 | 91,500 | -12,200 | -11.76% |
Dec 31, 2011 | 103,700 | -6,900 | -6.24% |
Dec 31, 2010 | 110,600 | -5,900 | -5.06% |
Dec 31, 2009 | 116,500 | 34,700 | 42.42% |
Dec 31, 2008 | 81,800 | -4,800 | -5.54% |
Dec 31, 2007 | 86,600 | -11,400 | -11.63% |
Dec 31, 2006 | 98,000 | -8,000 | -7.55% |
Dec 31, 2005 | 106,000 | -9,000 | -7.83% |
Dec 31, 2004 | 115,000 | -7,000 | -5.74% |
Dec 31, 2003 | 122,000 | 24,000 | 24.49% |
Dec 31, 2002 | 98,000 | 8,000 | 8.89% |
Dec 31, 2001 | 90,000 | 0 | - |
Dec 31, 2000 | 90,000 | 39,100 | 76.82% |
Dec 31, 1999 | 50,900 | 4,500 | 9.70% |
Dec 31, 1998 | 46,400 | -2,800 | -5.69% |
Dec 31, 1997 | 49,200 | 2,700 | 5.81% |
Dec 31, 1996 | 46,500 | 2,700 | 6.16% |
Dec 31, 1995 | 43,800 | 3,000 | 7.35% |
Dec 31, 1994 | 40,800 | 300 | 0.74% |
Dec 31, 1993 | 40,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
Elevance Health | 104,900 |
Medtronic | 95,000 |
Sanofi | 86,088 |
Novartis AG | 76,057 |
Danaher | 63,000 |
Amgen | 26,700 |
PFE News
- 17 hours ago - Pfizer, Genmab get full FDA approval for cervical-cancer drug - Market Watch
- 17 hours ago - TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer - Business Wire
- 17 hours ago - FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer - Business Wire
- 20 hours ago - US FDA grants full approval for Pfizer's cervical cancer drug - Reuters
- 1 day ago - Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting - Business Wire
- 3 days ago - What Factors Will Drive Pfizer's Q1 Performance? - Forbes
- 4 days ago - Pfizer Receives FDA Approval for Bleeding Disorder Treatment - Barrons
- 4 days ago - FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder - CNBC